<p>Proportion of RRMS patients with not evidence of disease activity (NEDA) under treatment with RTX (red) and NTZ (blue) over 30 months follow up.</p
Objectives. To evaluate the prevalence of clinical remission and minimal disease activity according ...
<p>Proportion of patients free of relapses (a), free of EDSS worsening (b), free of NT2 lesions (c) ...
Median prednisone dose among RT patients in their pre and post rituximab phases, and CAT-only patien...
<p>Only DMDs used in at least 10 SMSC patients and with at least 1 year of mean follow-up are shown....
<p>Changes of proportion of RRMS patients with Cognitive Impairment (CI) after 1–2 year Natalizumab ...
<p>Analysis on the proportion of patients with no evidence of disease activity at 2-years included i...
Cohort of RRMS patients after relapse treated with either Tecfidera or Beta Interferon who underwent...
Background: Over the last decade, therapy of relapsing remitting multiple sclerosis (RRMS) has evolv...
<p>Panel A shows the distribution of subjects according to their NBV and lesional-WM MTr. HC are in ...
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
<p>Patients were grouped according to the number of fulfilled parameters (corticosteroids therapy, n...
<p>RRMS = relapsing remitting multiple sclerosis at onset; NMO = neuromyelitis optica.</p
<p>RRF = Rate of relapse free patients after 2 years, SE = Standard error, ARR = Annualized re...
<p>Number of male and female RRMS/SPMS patients who provided at least one valid EDSS measurement in ...
We tried to determine which baseline variables are responsible for remission induction at 6 months i...
Objectives. To evaluate the prevalence of clinical remission and minimal disease activity according ...
<p>Proportion of patients free of relapses (a), free of EDSS worsening (b), free of NT2 lesions (c) ...
Median prednisone dose among RT patients in their pre and post rituximab phases, and CAT-only patien...
<p>Only DMDs used in at least 10 SMSC patients and with at least 1 year of mean follow-up are shown....
<p>Changes of proportion of RRMS patients with Cognitive Impairment (CI) after 1–2 year Natalizumab ...
<p>Analysis on the proportion of patients with no evidence of disease activity at 2-years included i...
Cohort of RRMS patients after relapse treated with either Tecfidera or Beta Interferon who underwent...
Background: Over the last decade, therapy of relapsing remitting multiple sclerosis (RRMS) has evolv...
<p>Panel A shows the distribution of subjects according to their NBV and lesional-WM MTr. HC are in ...
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
<p>Patients were grouped according to the number of fulfilled parameters (corticosteroids therapy, n...
<p>RRMS = relapsing remitting multiple sclerosis at onset; NMO = neuromyelitis optica.</p
<p>RRF = Rate of relapse free patients after 2 years, SE = Standard error, ARR = Annualized re...
<p>Number of male and female RRMS/SPMS patients who provided at least one valid EDSS measurement in ...
We tried to determine which baseline variables are responsible for remission induction at 6 months i...
Objectives. To evaluate the prevalence of clinical remission and minimal disease activity according ...
<p>Proportion of patients free of relapses (a), free of EDSS worsening (b), free of NT2 lesions (c) ...
Median prednisone dose among RT patients in their pre and post rituximab phases, and CAT-only patien...
DOI
Add to ORKG